NASDAQ:SGMO - Nasdaq - US8006771062 - Common Stock - Currency: USD
We assign a fundamental rating of 2 out of 10 to SGMO. SGMO was compared to 553 industry peers in the Biotechnology industry. SGMO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SGMO is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -149.17% | ||
ROE | -2620.02% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -28.28 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 0.76 | ||
Quick Ratio | 0.76 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
0.5616
+0.02 (+4.56%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 2.08 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 27.2 | ||
P/tB | 27.2 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -149.17% | ||
ROE | -2620.02% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 0.76 | ||
Quick Ratio | 0.76 | ||
Altman-Z | -28.28 |